Adalimumab
- Generic Name
- Adalimumab
- Brand Names
- Amjevita, Cyltezo, Humira, Hyrimoz, Yusimry, Hulio, Hefiya, Libmyris, Imraldi, Amsparity, Idacio, Hukyndra, Amgevita, Yuflyma
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 331731-18-1
- Unique Ingredient Identifier
- FYS6T7F842
- Background
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced by recombinant DNA technology usi...
- Indication
Adalimumab is indicated for the following conditions:
Adalimumab has also been used off-label to treat Pyoderma gangrenosum.
- Associated Conditions
- Ankylosing Spondylitis (AS), Hidradenitis Suppurativa (HS), Moderate to Severe Chronic Plaque Psoriasis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis, Non-infectious Intermediate, Posterior and Panuveitis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Pyoderma Gangrenosum
- Associated Therapies
- -
Comparison of Adalimumab and Infliximab Treatment of Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2009-08-18
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 112
- Registration Number
- NCT00216177
- Locations
- 🇩🇰
Hvidovre Hospital, Copenhagen, Denmark
🇩🇰Bispebjerg Hospital, Copenhagen, Denmark
🇩🇰Glostrup Hospital, Copenhagen, Denmark
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-04-13
- Lead Sponsor
- Abbott
- Target Recruit Count
- 1469
- Registration Number
- NCT00195676
- Locations
- 🇺🇸
Site Reference ID/Investigator# 1268, Tyler, Texas, United States
🇺🇸Site Reference ID/Investigator# 2434, Columbus, Ohio, United States
🇺🇸Site Reference ID/Investigator# 1683, Boston, Massachusetts, United States
A Pilot Trial of Adalimumab for the Treatment of Osteoarthritis
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2006-03-24
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 12
- Registration Number
- NCT00185562
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
TNFalfa Blocking Treatment of Spondylarthropathies
- Conditions
- First Posted Date
- 2005-08-23
- Last Posted Date
- 2007-04-10
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT00133315
- Locations
- 🇩🇰
Hvidovre University Hospital, Hvidovre, Denmark
🇩🇰Vejle Sygehus, Vejle, Denmark
🇩🇰Bispebjerg Hospital, Copenhagen, Denmark
Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease
- Conditions
- First Posted Date
- 2005-03-14
- Last Posted Date
- 2006-08-15
- Lead Sponsor
- Abbott
- Target Recruit Count
- 300
- Registration Number
- NCT00105300
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸SMC-Trauma Research, Englewood, Colorado, United States
🇺🇸Gastroenterology Associates of Cleveland, Mayfield Heights, Ohio, United States
Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2007-09-26
- Lead Sponsor
- Abbott
- Target Recruit Count
- 854
- Registration Number
- NCT00077779
- Locations
- 🇺🇸
Gastroenterology Associates of Fairfield County, Bridgeport, Connecticut, United States
🇺🇸Clinical Research of West Florida, Inc., Clearwater, Florida, United States
🇺🇸Mark Lamet, MD, Hollywood, Florida, United States
Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2002-11-14
- Last Posted Date
- 2006-08-15
- Lead Sponsor
- Abbott
- Target Recruit Count
- 3000
- Registration Number
- NCT00049751
- Locations
- 🇺🇸
Freeman Health Systems, Joplin, Missouri, United States
🇺🇸Rheumatology Clinic, Los Angeles, California, United States
🇺🇸Pain Therapy Center, Schaumburg, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.